GT Biopharma, Inc.
GTBP
$1.14
$0.000.00%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -45.81% | -64.00% | 1.21% | 30.66% | 39.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -61.26% | -37.50% | 18.78% | 15.44% | 7.87% |
| Operating Income | 61.26% | 37.50% | -18.78% | -15.44% | -7.87% |
| Income Before Tax | 61.37% | 65.75% | -27.45% | -41.18% | -86.24% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 61.37% | 65.75% | -27.45% | -41.18% | -86.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 61.37% | 65.75% | -27.45% | -41.18% | -86.24% |
| EBIT | 61.26% | 37.50% | -18.78% | -15.44% | -7.87% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 74.73% | 79.84% | 22.02% | 13.61% | -45.68% |
| Normalized Basic EPS | 76.15% | 53.87% | 22.18% | 13.73% | -44.05% |
| EPS Diluted | 74.73% | 79.84% | 22.02% | 13.61% | -45.68% |
| Normalized Diluted EPS | 76.15% | 53.87% | 22.18% | 13.73% | -44.05% |
| Average Basic Shares Outstanding | 61.90% | 69.86% | 63.44% | 63.42% | 27.85% |
| Average Diluted Shares Outstanding | 61.90% | 69.86% | 63.44% | 63.42% | 27.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |